

AWARD NUMBER:

W81XWH-18-1-0770

TITLE:

Clinical Qualification of DNA Repair Defects as Biomarkers in Metastatic Prostate Cancer Using Integrated Genomics and Tissue-Based Functional Assays

PRINCIPAL INVESTIGATOR:

David Olmos

CONTRACTING ORGANIZATION:

Fundación Centro Nacional de Investigaciones Oncológicas, Madrid, Spain

REPORT DATE:

October 2021

TYPE OF REPORT:

[Annual](#)

PREPARED FOR:

U.S. Army Medical Research and Development Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release; Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE			<i>Form Approved</i> <i>OMB No. 0704-0188</i>		
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE October 2021		2. REPORT TYPE Annual		3. DATES COVERED 30Sep2020-29Sep2021	
4. TITLE AND SUBTITLE Clinical Qualification of DNA Repair Defects as Biomarkers in Metastatic Prostate Cancer Using Integrated Genomics and Tissue-Based Functional Assays			5a. CONTRACT NUMBER		
			5b. GRANT NUMBER W81XWH-18-1-0770		
			5c. PROGRAM ELEMENT NUMBER		
6. AUTHOR(S) Olmos, David E-Mail: dolmos@cnio.es			5d. PROJECT NUMBER		
			5e. TASK NUMBER		
			5f. WORK UNIT NUMBER		
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) Fundación Centro Nacional de Investigaciones Oncológicas Melchor Fernández Almagro 3 Madrid 28029, Spain			8. PERFORMING ORGANIZATION REPORT NUMBER		
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Development Command Fort Detrick, Maryland 21702-5012			10. SPONSOR/MONITOR'S ACRONYM(S)		
			11. SPONSOR/MONITOR'S REPORT NUMBER(S)		
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT We and others previously described an enrichment for somatic and germline alterations in DNA damage repair (DDR) genes among men with metastatic prostate cancer. Several recent clinical studies have indicated many of these patients could benefit from precision medicine strategies with PARP inhibitors and DNA damaging agents. In this project, our teams would investigate genomic, transcriptomic and protein-related functional signatures for a more accurate sub-classification of prostate cancers associated to DDR defects, aiming for a more precise patient care. The project is divided in 3 main aims: 1) testing the prognostic value of somatic DDR defects in a retrospective cohort of tumor biopsies, 2) developing multi-omics signatures based on prospective analyses of metastatic biopsies and 3) clinical validation of these biomarkers in a clinical trial using carboplatin as DNA damaging chemotherapy.					
15. SUBJECT TERMS None Listed					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT	b. ABSTRACT	c. THIS PAGE			USAMRDC
Unclassified	Unclassified	Unclassified	Unclassified	34	19b. TELEPHONE NUMBER (include area code)

TABLE OF CONTENTS

	<u>Page</u>
1. Introduction	4
2. Keywords	4
3. Accomplishments	4
4. Impact	23
5. Changes/Problems	24
6. Products	26
7. Participants & Other Collaborating Organizations	30
8. Special Reporting Requirements	34
9. Appendices	34

10. INTRODUCTION:

We and others previously described an enrichment for somatic and germline alterations in DNA damage repair (DDR) genes among men with metastatic prostate cancer. Several recent clinical studies have indicated many of these patients could benefit from precision medicine strategies with PARP inhibitors and DNA damaging agents. In this project, our teams would investigate genomic, transcriptomic and protein-related functional signatures for a more accurate sub-classification of prostate cancers associated to DDR defects, aiming for a more precise patient care. The project is divided in 3 main aims: 1) testing the prognostic value of somatic DDR defects in a retrospective cohort of tumor biopsies, 2) developing multi-omics signatures based on prospective analyses of metastatic biopsies and 3) clinical validation of these biomarkers in a clinical trial using carboplatin as DNA damaging chemotherapy.

11. KEYWORDS:

Genomics; Whole-exome sequencing; RNAseq; Precision Medicine; DNA repair; BRCA; PARP inhibitors; platinum chemotherapy; clinical trial.

12. ACCOMPLISHMENTS:

What were the major goals of the project?

Specific Aim 1 – To correlate the presence or absence of somatic/germline alterations in DNA repair genes with overall survival from mCRPC, and specific response to taxanes, Abiraterone, Enzalutamide, and Rd223, in samples from a prospective study.

Major Task 1: Targeted NGS on all study samples	Timeline (Months)	Completed (%)
Preparation of tumor biopsies for DNA extraction	0-12	100%
Milestone 1.1 – Shipment of samples to UW Laboratory (batches)	3 to 15	70%
Library preparation for targeted NGS	3 to 20	70%
Sequencing of all samples from the PROREPAIR-B study	3 to 20	70%
Variant calling, bioinformatics analysis	3 to 20	70%

	Timeline (Months)	Completed (%)
Milestone 1.2 – Classification of each patients as “positive” or “negative” for each of the biomarkers of interest (BRCA1, BRCA2, ATM, PALB2)		
Sequencing data analysis board: identification of putative relevant calls for patient care and relatives’ risk of cancer	3 to 20	70%
Statistical analysis: correlation of genomic biomarkers with previously annotated clinical outcome data	22	20%
Milestone 1.3 – Data analysis and interpretation, Manuscript Preparation	24	20%
Milestone 1.4 - F2F meeting among participating sites to discuss progress	12	100%

Specific Aim 2 – To optimize tissue-based tests of HR functionality samples for CRPC samples, and study the correlation with genomic aberrations in HR genes.

Major Task 2: Acquisition of bone marrow metastatic biopsies	Timeline (Months)	Completed (%)
Harmonization of tissue acquisition protocol among participating sites	1 to 2	100%
Collection of 100 metastatic biopsies, samples are sent to sites 2 and 3	3 to 22	80%
Milestone 2.1 – Sample acquisition completed	23	75%
Major Task 3: Whole-exome sequencing studies		
DNA extraction from tumor and germline DNA	6 to 24	80%
Whole exome sequencing studies	12 to 26	60%
Variant calling, bioinformatics analysis	12 to 28	40%
Sequencing data analysis board: identification of putative relevant calls for patient care and relatives’ risk of cancer	6 to 30	10%
Major Task 4: Expression profiling studies		
RNA extraction from frozen core of biopsies	6-24	60%

RNA-seq studies	9 to 26	30%
Bioinformatics analysis	12 to 28	10%
Major Task 5: Immunofluorescence studies		
Sample preparation	8 to 30	90%
Immunofluorescence studies	10 to 30	75%
Milestone 5.1 – Integrated analysis of sequencing and IF data	32	50%
Milestone 5.2 – Data analysis and interpretation, Manuscript Preparation	34	0%

Specific Aim 3 To clinically qualify this HR functional test in a clinical trial of carboplatin in CRPC

Major Task 6: Clinical Trial Set Up	Timeline (Months)	Completed (%)
Clinical Trial Protocol Writing and Development	1 to 5	100%
Submission of clinical trial protocol to local ethics and regulatory bodies	5	100%
Set up of clinical sites participating in the trial		100%
Milestone 6.1 – First patient enrolled in the clinical trial	12	0%
Major Task 7: Clinical Trial conduction		
Patient recruitment	12 to 30	17%
Continuous data monitoring	12-36	4%
Trial-related biopsy acquisition	12 to 30	17%
Milestone 7.1 Recruitment completed for cohort 1	26	0%*
Milestone 7.2 Recruitment completed for cohort 2, stage 1	22	0%*

Recruitment for cohort 2, stage 2 (depending on results from stage 1)	23-30	0%*
Milestone 7.3 Recruitment completed for cohort 2, stage 2	30	18%
Major Task 7: Biomarker studies in trials samples		
Preparation of trial related biopsies for NGS studies	12 to 30	3%
Targeted sequencing in trial-related biopsies	12 to 30	3%
Variant calling, bioinformatics analysis	12 to 30	0%
Immunofluorescence studies	12 to 30	15%
Sequencing data analysis board: identification of putative relevant calls for patient care and relatives' risk of cancer	12 to 30	0%
Milestone 7.1 – Integrated analysis of clinical and biomarker data	34	0%
Milestone 7.2 – Data analysis and interpretation, Manuscript Preparation	36	25%

- See comment in the accomplished milestones for aim 3

What was accomplished under these goals?

Specific Aim 1 – To correlate the presence or absence of somatic/germline alterations in DNA repair genes with overall survival from mCRPC, and specific response to taxanes, Abiraterone, Enzalutamide, and Rd223, in samples from a prospective study.

Major Task 1: Targeted NGS on all study samples

In year 3, a major focus was to continue to optimize methods to allow clinical sequencing of very low input and low-quality DNA samples from the CNIO site. Major activities included review of an FFPE DNA repair step to improve DNA quality for sequencing (**Figure**), revision of the pooled hybridization capture protocol to include maximum input quantity in NGS, while reducing the control sample input (to avoid sinking DNA sequence), and exploration of low-input single-stranded NGS library prep protocol. In Year 3 we completed experiments using a new FFPE DNA repair protocol

on low quality samples. Following completion of these additional optimization experiments Site 1 will plan to complete sequencing of samples from CNIO.




Figure: Effect of FFPE DNA repair on UW-OncoPlex sequencing results. Example copy number plots of CNIO sample 010 run on the UW-OncoPlex v6 panel without (top, original) or with (bottom) FFPE DNA repair. Quality metrics were improved with the FFPE DNA repair step, including copy number quality

In addition, a *JAMA Oncology* study led by the Pritchard Group with regard to cell-free DNA sequencing in prostate cancer acknowledged support from this award was featured in many news media outlets.

To date, 4 batches of samples have been sent from CNIO to the UW site and UW-OncoPlex sequencing and 97 have had sequencing using our more optimized low input protocols as outlined below. Of these, 70 had adequate studies to call mutations despite very low input quantities and low DNA quality. Among these 7 had *BRCA2* mutations, 5 had *ATM* mutations, 1 had an *NBN* mutation, 2 had *CHEK2* mutations, 2 had *MUTYH* mutations, 1 had a *FANCA* mutation, and 1 had a *FANCC* mutation (**Table**).

Table: Prostate Cancer Samples with DNA Repair Gene Mutations Detected by UW-OncoPlex

CNIO_OLM_ID	UW Dataset_ID	DNA Repair Gene Mutation	Interpretation
OLM_03.035	198R16_H02_OPXV5_NB0187	ATM	POSITIVE for a pathogenic ATM mutation with associated LOH (p.R521*), CHD1 focal homozygous copy loss, possible MYC amplification
CNIOUW 012	272R10_B02_OPXV6_NA0414	ATM	POSITIVE for a pathogenic ATM mutation (p.R531*) with LOH (bi-allelic), CHD1 homozygous copy loss (bi-allelic), possible MYC amplification
CNIOUW 028	276R04_D01_OPXV6_NB0352	ATM	POSITIVE for two pathogenic ATM mutations (bi-allelic).
OLM_03.012	281R08_H01_OPXV6_NB0365	ATM	POSITIVE for ATM exon 25-63 del mutation with LOH (bi-allelic), CHD1 homozygous copy loss, SPOP p.F102I mutation
OLM_03.047	198R17_A03_OPXV5_NB0187	ATM VUS	POSITIVE for a pathogenic TP53 mutation, ATM VUS in the FAT domain (p.I2401T), and PTEN copy loss
OLM_01.006	198R01_A01_OPXV5_NB0187	BRCA2	POSITIVE for BRCA2 copy loss, cannot determine if 1 or 2 copies. Possible MYC amplification.
OLM_01.039	198R07_G01_OPXV5_NB0187	BRCA2	POSITIVE for a pathogenic mutation in BRCA2 (c.6650_6654del); cannot tell if germline or somatic
CNIOUW 005	272R03_C01_OPXV6_NA0414	BRCA2	POSITIVE for BRCA2 focal deletion (favor bi-allelic) and FOXA1 mutation
CNIOUW 018	275R06_F01_OPXV6_NB0350	BRCA2	POSITIVE for BRCA2 exon 1-24 deletion + LOH (bi-allelic) and possible MYC amplification.
CNIOUW 032	276R08_H01_OPXV6_NB0352	BRCA2	POSITIVE for a pathogenic BRCA2 mutation (c.3264dup), with possible BRCA2 copy loss.
OLM_FIVO.012	286R25_A04_OPXV6_NB0365	BRCA2	POSITIVE for a pathogenic BRCA2 mutation (cannot determine if mono-allelic or bi-allelic)
OLM_02.007	281R11_C02_OPXV6_NB0365	BRCA2?	POSITIVE for TP53 mutation, BRCA2 single copy loss, possible MYC amplification, and additional alterations
OLM_03.065	286R23_G03_OPXV6_NB0365	CDK12	POSITIVE for CDK12 bi-allelic pathogenic mutation with associated tandem duplication signature, MYC amplification, FOXA1 mutation
OLM_02.009	281R01_A01_OPXV6_NB0365	CHEK2	POSITIVE for a pathogenic mutation in CHEK2 (exon 11-12 deletion), cannot determine if mono- or bi-allelic
CNIOUW 034	277R02_B01_OPXV6_NB0354	CHEK2 VUS	POSITIVE for SPOP p.F102C mutation, KDM6A mutation, MYC amplification, and CHEK2 VUS.
OLM_FIVO.228	286R37_E05_OPXV6_NB0365	FANCA	POSITIVE for FANCA pathogenic mutation (cannot tell if mono-allelic or bi-allelic), TP53 mutation, and additional alterations
CNIOUW 039	277R07_G01_OPXV6_NB0354	FANCC	POSITIVE for a pathogenic mutation in FANCC (c.455dup, carrier only)
OLM_02.033	198R12_D02_OPXV5_NB0187	MLH1, MSI-high	MSI-high due to MLH1 loss, high total mutation burden.
CNIOUW 010	272R08_H01_OPXV6_NA0414	MSI/MMRd	MSI-high likely (limited analysis due to low sample quality)
CNIOUW 033	277R01_A01_OPXV6_NB0354	MUTYH (carrier)	POSITIVE for a pathogenic mutation in MUTYH (p.G396D, carrier only)
CNIOUW 009	272R07_G01_OPXV6_NA0414	MUTYH (carrier)	POSITIVE for a pathogenic mutation in MUTYH (p.G396D, carrier only)
OLM_FIVO.009	286R32_H04_OPXV6_NB0365	MUTYH (carrier)	POSITIVE for germline heterozygous MUTYH mutation (p.Y179C carrier), TP53 mutation, BRCA2 single copy loss, and additional alterations
CNIOUW 008	272R06_F01_OPXV6_NA0414	NBN	POSITIVE for a pathogenic mutation in NBN (p.R43*)

HRPO approvals: The research for Aim 1 at Site 1 (UW) was determined to be not human subjects by the UW IRB, with HRPO concurrence on 10/17/2018. This facilitated use of de-identified samples

from Site 2 in year 1 and year 2 for optimization of the UW-OncoPlex sequencing assay in the context of limited sample quantity. HRPO approval was obtained at Site 2 (CNIO) on 9/30/19 for research on aims 1 and 2.

In years 1 and 2 Site 1 (UW) received representative de-identified extracted DNA specimens from the Site 2 (CNIO) for UW-OncoPlex sequencing in batches to optimize sequencing protocols.

Many of the samples had low amounts of residual DNA remaining (<250ng). There is availability of pre-capture libraries for most of the samples. To facilitate adequate performance on these low input samples we undertook three parallel development efforts in year 1 to modify and re-validate the UW-OncoPlex assay for clinical use with low-input samples anticipated from the PROREPAIR trial as part of this work.

The first approach was to validate pre-capture libraries from Site 2 for use with UW-OncoPlex. To evaluate and validate pre-capture libraries as a sample type for UW-OncoPlex pilot samples were sent to Site 1 (UW) from Site 2 (CNIO) with matched pre-cap libraries and extracted DNA. We are currently working closely with our bioinformatics team, wet-bench staff to work out the protocol to run and analyze these pre-cap library samples on our platform. Briefly, the samples are quantified on the Agilent Tape Station and pooled together for hybridization along with a HapMap control (NA12878). They are hybridized with latest UW-OncoPlex (version 6) capture, using an IDT xGen protocol. The pool is loaded on an Illumina instrument (PE101 + 8bp index read). Since the samples were previously barcoded with 6bp indexes, we added “NN” to the end of the sequences for the MiSeq sample sheet, which would allow demultiplexing and analysis of both the 6bp and 8bp indexes in the pool. Using this protocol we have successfully sequenced four pre-capture libraries, however the sequencing quality is not yet adequate using pre-capture libraries. To troubleshoot, we are attempting more pre-capture libraries with higher DNA quantity. In parallel we focused on testing samples with >250ng input DNA, prioritizing patients with radical prostatectomy first.

The second approach was to modify and re-validate the UW-OncoPlex sequencing assay for use with Nextera NextFlex enzymatic tagmentation-based sequencing library preparation rather than using DNA shearing with the Covaris. This NextFlex method allows the assay to take as little as 10ng DNA input rather than the 250ng input desired with Covaris shearing method. Also, less DNA is lost in wash steps using the NextFlex method. Briefly, to validate this method at Site 1, we selected a total of 57 tumor DNA samples that had been previously characterized by UW-OncoPlex and re-ran these using the Nextera low input protocol. All reportable mutations, copy number variants, and structural variants were identified using the Nextera protocol. Between run and within reproducibility was assessed for 3 tumor samples and for the NA12878 HapMap control with perfect concordance. MSI status was also 100% concordant. An example of the qualitative concordance of copy number calling is given in the Figure below.




Figure: Comparison of copy number calling between the standard shearing and low input Nextera UW-OncoPlex sequencing. We observed high qualitative and quantitative concordance between the standard shearing-based library prep and Nextera low input library preparation for the UW-OncoPlex assay.

Finally, as a third approach, we will explore testing plasma cell-free DNA for patients <250ng input DNA remaining. The CNIO group at Site 2 has frozen plasma available from most of these patients and is currently exploring whether it may be feasible to use these samples. The UW-OncoPlex assay has recently been extensively clinically-validated for use with plasma cell-free DNA in patients with metastatic prostate cancer (Schweizer et al. 2019 PMID:30865311, DOD support acknowledged). In parallel, and for those PROREPAIR-B cases without cell-free DNA samples and poor quantity/quality DNA yields, Site 2 (CNIO) will explore to complement the results with shallow whole genome sequencing (WGS) which may yield results satisfactory enough to detect chromosomal deletions which cause loss of function in the genes of interest, in some genes as *BRCA2* this large deletion are the commonest somatic change. At the present a small cross validation of both UW-OncoPlex sequencing at site 1 and shallow WGS has been completed as part of an initial PROREPAIR report in ASCO and ESMO annual meetings (Lozano et al. 2021, DOD support acknowledged) and which a manuscript has been submitted.

For the no cost extension period we decided to start the alternative plan to sequence the plasma circulating DNA from those patients which lack adequate tumor tissue, or in which extracted DNA did not yield the minimum quantity or quality for NGS analysis or quality. At site 1 we have started identifying those cases in which we have available plasma samples for processing and DNA extraction. This samples will be then sent to UW (Site 1)

During year 3, We implemented a technical improvement to the UW-OncoPlex panel that included the additional of a validated Homologous Recombination DNA repair (HRD) signature analysis using global burden of LOH, in the UW-OncoPlex version 7 panel update that went live at the end of Year 3 Q3 (**Figure**).




Figure: Comparison of HRD analysis by UW-OncoPlex (X-axis) compared to a commercial lab approach (Y-axis)

In summary, major activities in year 3 included review of an FFPE DNA repair step to improve DNA quality for sequencing, revision of the pooled hybridization capture protocol to include maximum input quantity in NGS, while reducing the control sample input (to avoid sinking DNA sequence), exploration of low-input single-stranded NGS library prep protocol, preparation for cell-free plasma DNA testing, and improvement of the UW-OncoPlex panel by the addition of HRD mutation signature analysis.

Summary of progress on milestones related to Aim 1 in Year 3

Milestone 1.1 Shipment of samples From CNIO laboratory to UW laboratory (batches) (Month 3-15): In summary, four batches of samples were shipped from CNIO to the UW Laboratory, focusing on samples with the highest quantity of residual DNA. Batches of de-identified samples were initially shipped for the purpose of assay and protocol optimization from Site 2 to Site 1 in year 1 (not human subjects research) while HRPO approval at site 2 was pending. The PROREPAIR-B trial in which aim 1 was based, was an already approved and completed protocol in Spain. There were some unanticipated delays in obtaining HRPO approvals at Site 2 (CNIO) due in part to requirements of independent evaluation of this work by our reference IRB, and review of several iterations of verified English translations from original study documents produced in Spanish between January and July 2019. After submission of the final required documents in July 2018, HRPO approval at Site 2 (CNIO) was granted on September 30th, 2019.

Since receiving HRPO approval at Site 2 (CNIO), 217 samples were reviewed by a trained GU pathologist, macro-dissected from tumor sections and processed for DNA extraction at the CNIO Lab. These were archived biopsies from multiple participating sites (38) which were obtained primary for pathology diagnosis a median of 2 years (range 4-21 years) before developing mCRPC and entering the study the tumor tissue availability was scarce in many previously devastated tumour blocks, or the DNA quantity and quality yield by these samples was low in most cases. After discussion with the Site 1 UW laboratory, and following progress in improving the UW-OncoPlex assay to work with samples with lower DNA quantity/quality as expected from PROREPAIR-B FFPE sample collection. Shipments were organised according to quality/quantity starting with best samples from initial 120 extracted samples.

Milestone 1.2 – Classification of each patients as “positive” or “negative” for each of the biomarkers of interest (BRCA1, BRCA2, ATM, PALB2): To date, we have identified 23 patients as “positive for

the biomarker” of interest, using sequencing done at site 1 (see Table 1), 12 additional patients with alterations limited to *BRCA2* (gene deletions) has been identified at site 2 using alternative approaches as described above.

Milestone 1.3 – Data analysis and interpretation, Manuscript Preparation
(24 months; Site 1, 2 and 3):

Two initial communications related to aim 1 have already been presented at international meetings in which the DOD funding has been acknowledged:

1. Meeting: 27th Prostate Cancer Foundation Scientific Retreat, October 20-23, 2020

- **Title:** *Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer*

- **Authors:** E. Castro, D.C. Salles; R. Lozano, H. Thorne, F. López-Campos, J. Rubio-Briones, Ana M. Gutierrez-Pecharroman, M.I. Pacheco, T. Garcés, N. Romero-Laorden, F. Zambrana, P.P. López-Campos, S. Sandhu, **J. Mateo, C. Pritchard**, E. Antonarakis, **D. Olmos**, T. Lotan.

- **Reference:** <https://www.morressier.com/article/association-brca2-alterations-intraductal-cribriform-histologies-prostate-cancer/5f69edb69b74b699bf38c600?>

2. Meeting: European Society of Medical Oncology annual meeting 2020, September 19-21, 2020 (also presented at the American Society of Clinical Oncology annual meeting, May 27-Jun 1, 2020)

- **Title:** *Clinical impact of somatic alterations in prostate cancer patients with and without previously known germline BRCA1/2 mutations: Results from PROREPAIR study*

- **Authors:** R. Lozano Mejorada, E. Castro Marcos, I.M. Aragón, H. Thorne, F. Lopez Campos, A. Sanz, C. Alonso, U. Anido, M.J. Juan Fita, A.M. Gutierrez Pecharromán, M. Ramirez-Backhaus, J. Balmana, I. Chirivella Gonzalez, G. Llort, N. Romero Laorden, S. Arevalo Lobera, J. Rubio Briones, **J. Mateo, C.C. Pritchard**, S. Sandhu, **D. Olmos Hidalgo**

- **Reference:** <https://doi.org/10.1016/j.annonc.2020.08.872>

A manuscript based on the PROREPAIR samples and the results in abstract 1 was accepted for publication in the European Journal of Cancer on January 25th, 2021:

- **Title:** Association between BRCA2 alterations and intraductal and cribriform histologies in prostate cancer

- **Authors:** R. Lozano, D.C. Salles, S. Sandhu, I.M. Aragón, H. Thorne, F. López-Campos, J. Rubio-Briones, A.M. Gutierrez-Pecharroman, L. Maldonado, T. di Domenico, A. Sanz, J.D. Prieto, I. García, M.I. Pacheco, T. Garcés, C. Llacer, N. Romero-Laorden, F. Zambrana, P.P. López-Casas, D. Lorente, J. Mateo, C.C. Pritchard, E.S. Antonarakis, D. Olmos, T.L. Lotan, E. Castro

DOI: <https://doi.org/10.1016/j.ejca.2021.01.027>

DOD funding was acknowledged as part of the submitted manuscript.

A manuscript related to Abstract 2 would be submitted in the weeks following this report. DoD funding would also be acknowledged on it.

Milestone 1.4 - F2F meeting among participating sites to discuss progress

(12 months; Site 1, 2 and 3): A project Kick-Off meeting with three PIs (Pritchard, Olmos, and Mateo) and with some co-investigators (Cheng and Castro) was held in San Diego, CA in Oct 2018. An end-of-year 1 meeting to discuss progress was held Oct 25th 2019 in San Diego, California, that included the three PIs, according to the planned timelines. A grant review meeting that included the three partnering PIs and key team members was held September 21, 2020.

During Year 3 we had several virtual meetings, 1 regular bi-monthly meeting between site 2 and site 3 to improve coordination for aims 2 and 3, and 2 meetings with teams from site 1, site 2 and site 3 in June and September 2021.

Specific Aim 2 – To optimize tissue-based tests of HR functionality samples for CRPC samples, and study the correlation with genomic aberrations in HR genes.

Major Task 2: Acquisition of bone marrow metastatic biopsies

For Site 2 (CNIO): IRB approval for the participation of site 2 at this major task (2.2) was received on November 26th, 2018 with the approval to proceed with aim 1. As outlined in the section above HRPO approval for aim 1 and 2 was received September 30th, 2019. Biopsies from twenty-three cases with metastatic disease that underwent biopsy of their metastatic disease has been identified at site 2, patient has been consented to use remnant tissue under the DoD protocol and samples will be shipped to Site 3 during the first semester of Y4.

For Site 3 (VHIO), the research protocol for acquisition and analysis of patient biopsies was approved by the local ethics board. As of 20th Jan 2022, 196 patients have been consented for consideration of biopsies. After discussion of suitability with interventional radiology, 68 patients have successfully undergone a metastatic biopsy procedure, collecting at least 1 fresh frozen core and 1 FFPE core for the study. Additionally, archival prostate primary tumor biopsy material has been retrieved from the diagnostic hospital for 120/196 cases. Saliva samples for correlative germline analyses were collected for all patients at the time of consent

Major Task 3: Whole-exome sequencing studies

DNA has been extracted from both tumor and saliva samples for all acquired biopsies, and low-pass whole-genome sequencing has been performed in all of them. Samples with a tumor content over 20%, estimated by low-pass WGS bioinformatics analysis have been selected for WES. As of Feb 2022, we have completed and analyzed whole-exome sequencing for 43 fresh biopsies included in this study.

Major Task 4: Expression profiling studies

RNA extraction from the frozen blocks of the metastatic biopsies was started in Sept 2020. Unfortunately, this represented a significant delayed from the original planned calendar, resulting from the complete shutdown of our lab at site 3 (VHIO) for over 3 months and later partial re-opening, due to the COVID19 pandemic-related restrictions, that made us prioritize other projects with prospective sample collection. Similarly, work for this task at site 2 (CNIO) was severely disrupted

due to the Covid-19 pandemic in Spain, the lab was closed from March 7th, 2020 until July 1st, 2020 under the government regulations. During the rest of year 2 and the most of year 3 the work site 2 for this task was delayed to due to staffing (see section 5 Changes and problems during the project at site 2).


At site 3, during year 3 we have extracted RNA and prepared RNA libraries for all acquired biopsies in the study. As of Feb 2022, we have successfully completed RNAseq on 51 fresh biopsies. of June 2021.

To maximize the number of evaluable samples in this study, during Year 3 we worked in optimizing protocols for RNAseq from RNA extracted from FFPE material. In our study, both FFPE and fresh-frozen blocks are acquired for each biopsy; however, the tumor content and RNA yield may vary from one core to another in the same biopsy procedure. Hence, implementing FFPE-RNAseq may increase the number of evaluable samples.

During no cost extension year (year 4) we will pursue the correlative analysis of the WES and RNAseq studies as detailed in the research plan. We will try to increment the cohort size by adding biopsies collected in Q1-2022 that have not been yet processed and with samples that may be provided by Site 2, as stated in the research plan.

Major Task 5: Immunofluorescence studies

As planned, we have re-optimized now an IF-based test initially developed in breast cancer patient-derived xenoinplant models and then validated in breast cancer biopsies (Cruz et al, Ann Onc 2018; Castroviejo-Bermejo et al, EMBO Med 2019). We are using FFPE slides from prostate cancer primary and metastatic biopsies. An overview of the assay procedure and interpretation workflow is presented below:




We evaluated baseline HRR function based on detection of RAD51 and γH2AX foci in geminin-positive tumor cells by immunofluorescence (IF). All samples were scored by two trained readers blinded to genomic and clinical data. Samples were considered HRR deficient (HRD) when RAD51 scores were low, pre-defined as <10% tumor cells presenting ≥5 RAD51 foci/cell.

We have now completed the RAD51 IF studies in 137 samples corresponding to 114 individual patients from this study. RAD51 IF has been completed for all patients for whom WES/RNaseq analysis were pursued, from the same biopsy block when feasible. In cases where the biopsy was insufficient, had low tumor content, or also for those patients who consented but did not have a biopsy done, we pursued RAD51 IF in the archival material available (in those cases, we are pursuing targeted NGS to complement the genomics-IF correlation).

Of 137 samples tested, 29 samples (21%) were deemed not evaluable due to low tumor content or insufficient number of germline-positive cells for RAD51 evaluation, as per the QC criteria described in the figure above. Additionally, there are 32 samples for which the staining has been done but the final report with results has not been yet issued at the time of writing this report. Hence, this report includes results for 76 samples from 68 individual patients.


As observed in the graph below, 22% of the tested samples had a RAD51 score lower than 10%, being considered then HR-deficient for the criteria of this study. The high levels of γ H2AX, a marker of DNA damage, across the cohort (represented with blue dots in the plot below) are reassuring that the cases with RAD51 negativity represent probably true HR-deficient cases and are not an artifact due to low baseline damage.




In parallel, we managed to test the assay in a further cohort of samples from metastatic prostate cancer patients enriched for DNA repair gene mutations. In particular, primary or metastatic biopsies from 52 men with metastatic prostate cancer who participated in the phase II TOPARP clinical trial of olaparib (results published in Mateo et al, Lancet Onc 2020) were made available to us.


The methodology for the gH2AX and RAD51 evaluation is the same as in the previous cohort. The association of the RAD51 score, response to olaparib and survival (radiographic progression-free survival, rPFS, and overall survival, OS) was analyzed by Chi-Square and log-rank tests.

Results: RAD51 and γ H2AX were successfully scored in 52 cases, in the same biopsies previously used for NGS in the clinical trial. All tumors showed abundant DNA damage (γ H2AX scores >40%). The intra-class correlation score (ICC) between the two blinded readers was 0.88. Overall, 22 of 52 (42%) cases were considered as HRD based on low RAD51 scores. Response rate (based on the composite RECIST/PSA/CTC trial criteria) was 15/22 (68%) vs 7/30 (23%) for patients with low vs high RAD51 scores ($p=0.001$). Patients with low RAD51 scores also had longer rPFS (median 9.3 vs 2.9 months $p=0.002$) and overall survival (median 17.4 vs 9.5 months, $p=0.05$) from initiation of olaparib. All 16/16 cases with BRCA1/2 alterations were identified as RAD51 low (Figure below). For patients with *PALB2* mutations, 2/2 patients with biallelic loss showed RAD51 low scores and responded to olaparib, whereas 2/2 patients with monoallelic *PALB2* mutations showed RAD51 high scores and did not respond to olaparib. Mutations in *ATM* and *CDK12* did not associate with low RAD51. Indeed, 10/11 *ATM*-mutated and 8/10 *CDK12*-mutated tumors presented high RAD51 scores; RECIST/PSA responses were observed in two patients with *ATM* mutations and high RAD51 scores.





Additionally, we have analyzed the inter-reader reproducibility of the assay, finding a 100% concordance using a dycotomic positive/negative calling, and high correlation ($R=0.896$) using a continuous variable calling between two blinded operators. At present, we are working in automatizing the reporting of results, in collaboration with our Pathology core services at VHIO; in order to expedite the development of the assay, we have now employed a pathologist (Dr Maria Urbanowicz) who work part-time in this project, but costs of this additional personnel will be covered by other sources, and not from this award.



These results were presented at the 2021 AACR Meeting, and a manuscript has been published in Cancer Discovery:

- Carreira S, Porta N, Arce-Gallego S et al. Biomarkers Associating with PARP Inhibitor Benefit in Prostate Cancer in the TOPARP-B Trial. 2021. Cancer Discovery. doi: 10.1158/2159-8290.CD-21-0007

Summary of progress on milestones related to Aim 2 in Year 2

Milestone 2.1 – Sample acquisition completed (month 23): Not completed, currently at 80%

Milestone 5.1 – Integrated analysis of sequencing and IF data (month 32): 25%

Milestone 5.2 – Data analysis and interpretation, Manuscript (month 34): To be pursued in Year 4.

Specific Aim 3 – To clinically qualify this HR functional test in a clinical trial of carboplatin in CRPC

Major Task 6: Clinical Trial Set Up


In year 1, we completed the trial protocol which was initially submitted to site 2 reference IRB (CEI Provincial de Malaga) and the AEMPS (Spanish regulatory agency) and initial review and proposed amendments were received by October 2020. The protocol was submitted to the HRPO before regulatory submission, but final feedback from HRPO was received in January 2020. These feedbacks were implemented together with the initial feedback from reference IRB and AEMPS and resubmitted for evaluation to both. Final IRB and AEMPS approvals of amended clinical trial documents were granted on March 27th and April 20th, 2020, respectively. The original documents and their verified translations of these documents were submitted to HRPO.

Following these approvals contract negotiations with participating sites were initiated by the CNIO team from July 1st, 2020, as the trial office was also in shutdown until July due to the government restrictions related to the COVID pandemic and the effects in the Spanish National Health System.

The first patient on trial started screening in March and was enrolled in study. However, initiation of some sites was delayed due to an unexpected sick leave of the study trial manager. By September 2021 all sites except 1 (H.U. La Princesa) were initiated (see site status list below in the next major task)

Major Task 7: Clinical Trial conduction

By end of October 2021, 28 patients have entered pre-screening, 23 patients have been screened and 20 patients have been successfully enrolled and received at least 1 dose of Carboplatin in the study. Two these 20 patients were enrolled in Cohort A (post-PARPi), 4 in Cohort B and 14 in Cohort C (see trial design below).



The summary of the clinical trial status is as follows:

1. 10 sites have consented and/or enrolled at least 1 patient
 - Hospital Universitario Virgen de la Victoria de Málaga: 6 patients consented, 1 screening failure (SF), 4 enrolled
 - Hospital Universitario Vall D'Hebron, Barcelona (site 3): 2 patients consented and 1 enrolled
 - Hospital Clínico San Carlos, Madrid, 1 patient consented and 1 enrolled
 - Hospital Provincial de Castellon, 1 patient consented and 1 enrolled
 - Instituto Catalan de Oncología, L'Hospitalet, 4 patients consented, 1 SF and 3 enrolled
 - Centro Oncológico de Galicia, La Coruña; 2 patients consented and 2 enrolled
 - Hospital del Mar, Barcelona, 2 patients consented, 1 enrolled
 - Instituto Oncológico de Donostia, San Sebastian, 2 patients consented and 2 enrolled
 - Instituto Valenciano de Oncología, Valencia, 2 patient consented and 2 enrolled

- Hospital Universitario 12 de Octubre, Madrid, 5 consented, 1 SF and 3 enrolled
- 2. 3 sites have not consented any patient by end of Year 3
 - o Instituto Catalan de Oncología, Badalona
 - o Hospital Universitario de Santiago, Santiago de Compostela
 - o Hospital Universitario Puerta del Hierro, Madrid

By end of Year 3 we have achieved at least 17% enrolment, although we cannot yet anticipate the potential impact in the recruitment of the 5th and futures COVID-19 waves in Spain, as restriction policies have been relaxed since June 2021 and especially after the end of the summer the recruitment in the trial is taking speed.

Trial conduction has not been initiated pending on completing contracts signatures with the participating sites. On other hand pre-initiation on site or virtual visits to train and evaluate the research team at each trail site has been completed.

Following the anticipated plans described in the quarterly reports during year 3, we have the support of CRIS Cancer Foundation and site 2 institution to initiate the sponsor transfer as soon as we gain approval from HRPO/CDMRP. This sponsor change will not involve additional cost over the budget. We have also contacted and confirmed 6 new additional sites in Spain: Hospital Universitario de Salamanca, Hospital Universitario Marques de Valdecilla-Santander, Hospital Costa del Sol – Marbella, Hospital Universitario de Valme – Sevilla, Hospital San Pedro de Alcántara - Cáceres , and Complejo Hospitalario de Navarra. In addition, we have contacted 4 potential sites in Italy: Azienda Ospedaliero Universitaria Maggiore della Carità, Novara; Istituto Oncologico Romagnolo, Meldola; Istituto Nazionale di tumori, Milano; and Candiolo Cancer Institute, Turin

Major Task 8: Biomarker studies in trials samples

Prospective allocation of patients to the different study cohorts is based on the RAD51-IF assay performed at Site 3 (VHIO).

As of November 2021, Site 3 has received 36 tumor samples from 24 individual patients who consented for trial participation as part of their prescreening or screening procedures. For some patients, more than one sample was tested due to 1) the trial biopsy block received was deemed not evaluable and a second block was sent; or 2) some trial sites sent to the central lab the archival biopsy and the fresh biopsy in parallel. For those cases, the result on the fresh sample was prioritized for trial enrolment.

Of 36 samples, 22 were prostate biopsies, 8 were bone metastasis biopsies, 4 were lymph node biopsies and 2 were liver biopsies.

For the 24 patients enrolled, RAD51-IF negativity (suggestive of HR defects) was detected in 3 patients (5 samples from 3 patients), and RAD51-IF positivity (suggestive of no HR defects) was observed in 15 cases (19 samples from 15 cases). For the remaining 6 patients, results were deemed as inconclusive or samples were considered not evaluable for technical reasons.

Additionally samples from biopsies and plasm has been gathered to preform NGS analysis with the UW-OncoPlex assay, they will be submitted during Y4Q1 to site 12 to complete analyses.

Finally, exploratory RNAseq analysis is undergoing in a small subset of tumor samples from the first 10 clinical trial patients enrolled. These analyses are performed in collaboration with GENYO-GFranada University (Spain), as a potential future new partner/subawardee. As explained during aim 2 achievements narrative, Site 2 was hampered to continue this work onsite by reasons largely explain in section 5.

- ***Summary of progress on milestones related to Aim 3 in Year 3***

Milestone 6.1 – First patient enrolled in the clinical trial (12 m): achieved at month 30

Milestone 7.1 (Originally Cohort 1, step 1) Recruitment completed for cohort A (n=18) – (48): 11%

Milestone 7.2 (Originally Cohort 1, step2) Recruitment completed for cohort B (n=25) – (46): 17%

Milestone 7.3 (Originally Cohort 2) Recruitment completed for cohort C (n=78) – (48): 18%

Milestone 8.1 – Integrated analysis of clinical and biomarker data (48): Not/A

Milestone 8.2 – Data analysis and interpretation, Manuscript Preparation (48+6): N/A

What opportunities for training and professional development has the project provided?

- **Site 1 (UW):** Gavin Ha, PhD recent junior faculty member recruit at the Fred Hutchinson Cancer Center who had collaborated with the Pritchard site on the UW-OncoPlex assay was awarded a 2019 Prostate Cancer Foundation Young Investigator Award. Jonathan Reichel, PhD, a postdoctoral fellow in the Pritchard group has received mentorship in bioinformatics for UW-OncoPlex. In June 2020, Heather Cheng, MD, PhD, co-investigator received a special NCI career development award for Cancer Clinical Investigator Team Leadership to make complex cancer research information more approachable. A Laboratory Medicine Masters Student, Mohammad Adil has continued training to learn how to analyze UW-OncoPlex data. A molecular genetic pathology fellow, Regina Kwon MD has been trained on UW-OncoPlex prostate cancer variant interpretation and leading the molecular tumor board.
- **Site 2 (CNIO):** Elena Castro, MD, PhD, investigator at site 2 was awarded a Juan Rodés Clinician Scientist fellowship from ISCIII (Spanish NIH) to continue working in the area of this project and DNA repair in Prostate Cancer during Year 1. At year 3, her fellowship was evaluated and renewed for an additional year. During the 4th quarter of Year 3 Q3, Daniel

Alameda joined site 2 team with an EU funded post-doctoral researcher fellowship. He will support them with bioinformatics and genomics work in aims 1 and aims 2 from Hospital 12 de Octubre, the new site that Dr. Olmos will be joining as PI by the end of 2022

- **Site 3 (VHIO):** Sara Arce, laboratory technician at Site 3 participating in this project, has been awarded a PhD fellowship to conduct her PhD in part related to this project under the mentorship of PI J. Mateo, and her role as technician in this project was taken over by Sarai Cordoba, PhD. Sara Arce remains involved in the project by acting as 2nd reader for all the RAD51 IF assays. Dr Daniel Aguilar has joined the team as bioinformatician dedicated to this project, starting May 2021. Dr Sara Simonetti, MD PhD, Pathologist, has joined the project as senior researcher (part-time dedicated to this project), to provide support in evaluating challenging cases from the pathology-immunofluorescence perspective.

How were the results disseminated to communities of interest?

- **Site 1 (UW):** Nothing to report.
- **Site 2 (CNIO):** This project has been discussed with other projects at a virtual Patient Engagement Event hold in Málaga in September 2020 co-organized by the CNIO team and the CRIS foundation, a cancer research charity. The attendance to this virtual meeting was estimated in 115.
- **Site 3 (VHIO):** J Mateo has participated in virtual Dissemination Events organized by the FERRO Foundation directed at employees of Mango and CocaCola Europe, talking about prostate cancer in general and this project in particular. Also, Sara Arce, PhD student in this proposal, participated in an event annually organized by VHIO for primary and secondary schools in Barcelona, where she presented her group to undergraduate students.

○

What do you plan to do during the next reporting period to accomplish the goals?

Site 1 (UW): For Aim 1, we anticipate completing UW-OncoPlex testing for PROREPAIR-B samples with the available and adequate DNA is available. For Aim 3, we anticipate beginning to receive samples for targeted sequencing from Site 3 during Y4 (no cost extension year). As we

progress toward the characterization of 100% of cases in aim 1 and aim 3, we will shift our focus to data analysis and manuscript preparation.

Site 2 (CNIO): The team at site 2 will be moving during Y4Q1 from CNIO to a new institution, and once this is complete we probably would need to ask to transfer the grant to the new institution. From our new institution (Hospital 12 de Octubre), we plan to send to site 1 the samples required to complete the analysis in aim 1 (between Q1 and Q3). At our new institution, we anticipate access to extra resources (including pathology and technicians' hours) to accelerate sample review and sample shipment. We will also finish the collection of additional samples for aim 2 to support the work led in aim 2 at site 3, and finally we will focus our greatest effort in advancing the clinical trial in aim 3 by transferring the sponsorship to CRIS foundation, enrolling new sites and contacting a professional CRO to overcome potential limitations at CNIO.

Site 3 (VHIO): During this last year of award, we will prioritize the combined analysis of WES+RNAseq data for the samples already analyzed. In order to expand the RAD51-IF tested cohort, we are pursuing targeted sequencing for those sample where the archival material did not allow for WES. That way, we anticipate being able to present integrative genomics-IF report for a larger cohort that initially planned.

4. IMPACT:

What was the impact on the development of the principal discipline(s) of the project?

There has been significant interest in our results demonstrating 1) the power of functional RAD51 foci assays to predict homologous recombination DNA repair deficiency, 2) our work on the PROREPAIR study as it relates to novel insights into the predictive value of BRCA2 and other homologous recombination DNA repair genes in prostate cancer, and 3) our work with UW-OncoPlex assay has garnered attention through highlighting the issue of false positives among HRD genes in cell-free plasma DNA testing in prostate cancer due to clonal hematopoiesis interference.

What was the impact on other disciplines?

Site 1 PI Dr. Colin Pritchard received a prestigious award from Scientific American, the 'C2 Catalyst for Precision Medicine Award', in recognition for his leadership in molecular diagnostics – particularly in the area of DNA repair gene assays and dissemination into the community.

What was the impact on technology transfer?

Nothing to report

What was the impact on society beyond science and technology?

Nothing to report

5. CHANGES/PROBLEMS:

Changes in approach and reasons for change

The current COVID-19 pandemic we are suffering worldwide has impacted the progress of this project at different levels: firstly, as our laboratories have been working at reduced capacity, or even under strict lockdown for some time, some of the analysis have been delayed. Secondly, the capacity to pursue research biopsies from patients at Site 2 and 3 were severely reduced during the period March-July due to the restrictions in our hospitals and the need for reducing the non-COVID related clinical activities and concerns about patient safety. At present, our sites still suffer from some limitations with regards to pursuing research biopsies, albeit not as strict as during Q2-Q3 2020. However, it is envisioned the second wave of COVID cases, currently affecting Europe severely may result again in more strict restrictions to the acquisition of research biopsies in the next few months. Last, the lockdown also has reduced the activates of our trials offices, delaying the setup of the clinical trial in Aim 3.

In order to minimize the impact of these restrictions in our progress, we have implemented diverse measures such as: 1) pursuing the validation of RAD51 IF assay in a separate cohort of metastatic biopsies with targeted genomics data available at Site 3; 2) prioritize exploiting publicly available transcriptomics databases, so the analysis can be conducted faster once we acquire the necessary biopsies.

Actual or anticipated problems or delays and actions or plans to resolve them

As outlined above, we developed additional protocols and alternative strategies for use with low input DNA quantity as many of the PROREPAIR-B samples have limited DNA. In parallel, we prioritized sequencing of samples from patients with high input DNA. As third option, in the no cost extension year we will now prioritize ctDNA from plasma samples when available.

Due to the COVID pandemic, the recruitment of patients and biopsy acquisition was severely restricted during 2020. After having been awarded a no-cost extension, recruitment was accelerated again in Q3-Q4 2021.

In addition, and as described above and in prior reports the activation of the Clinical Trial embedded in Aim 3 has delayed due to the Covid-19 pandemic in addition to recent changes in the legal frame for conducting clinical trials which difficult role as sponsor of CNIO.

Finally, in year 3 the institution of site 2 (CNIO) decided to deprioritize in investment in prostate cancer research, and therefore site 2 PI (David Olmos) and his team has been invited to move to a new institution by September 2021. Site 2 (CNIO) scientific management also experienced significant challenges in supporting the tasks in this grant in year 3, especially the clinical trial embedded in aim 3, which was exacerbated by the crisis provoked by COVID-19 pandemic in Spain. Due to the increasing difficulties to continue the grant of CNIO (site 2), the Site 2 PI and the prostate research team have proposed to change the site 2 sponsor to a third party “CRIS Cancer Research Foundation” a non-for-profit cancer research-oriented NGO. As part of the planned amendment to complete the sponsor transfer, we will add new trial sites in order to achieve the study enrollment trial in a shorter timeframe.

With regard to Dr. David Olmos as PI for site 2 and his team moving institutions, negotiations with the new institution “Research Institute Hospital 12 de Octubre (i+12)” in Madrid has advanced positively and the team is aiming to move to this new institution by December 2021. The CDMRP grant officer has been informed and the possibility to transfer the grant to this new institution has been proposed.

Changes that had a significant impact on expenditures

None

Significant changes in use or care of human subjects, vertebrate animals, biohazards, and/or select agents

Significant changes in use or care of human subjects
Not applicable

Significant changes in use or care of vertebrate animals
Not applicable

Significant changes in use of biohazards and/or select agents
Not applicable





6. PRODUCTS:


- Year 3:
Schweizer MT, Sivakumar S, Tukachinsky H, Coleman I, De Sarkar N, Yu EY, Konnick EQ, Nelson PS, **Pritchard CC**, Montgomery B. Concordance of DNA Repair Gene Mutations in Paired Primary Prostate Cancer Samples and Metastatic Tissue or Cell-Free DNA; JAMA Oncology; 7: 2021; 1-5; acknowledgement of federal support (yes).
Rebeca Lozano, Daniela C. Salles, Shahneen Sandhu, Isabel M. Aragón, Heather Thorne, Fernando López-Campos, José Rubio-Briones, Ana M. Gutierrez-Pecharroman, Tomas di Domenico, Alejandro Sanz1, Juan Daniel Prieto, Isabel García, María I. Pacheco, Teresa Garcés, Casilda Llacer, Nuria Romero-Laorden, Francisco Zambrana, Pedro P. López-Casas, David Lorente, **Joaquin Mateo, Colin C. Pritchard**, Emmanuel S. Antonarakis, **David Olmos**, Tamara L. Lotan, **Elena Castro**. Association between BRCA2 alterations and

intraductal and cribriform histologies in prostate cancer; European Journal of Cancer; 147: 2021; 74-83; acknowledgement of federal support (yes).

Jensen K, Konnick EQ, Schweizer MT, Sokolova AO, Grivas P, Cheng HH, Klemfuss NM, Beightol M, Yu EY, Nelson PS, Montgomery B, and Pritchard CC. Clonal Hematopoiesis in DNA Repair Genes Substantially Interferes with Prostate Cancer Plasma Cell-free DNA Testing. JAMA Oncology; 7:2021:107-110; published; acknowledgement of federal support (yes). **This study is currently featured on the CDMRP PCPR website homepage under “News & Highlights”.**

Michael T. Schweizer, Smruthy Sivakumar, Hanna Tukachinsky, Ilsa Coleman, Navonil De Sarkar, Eric Q. Konnick, Peter S. Nelson, **Colin C. Pritchard**, R. Bruce Montgomery. Concordance of DNA Damage Repair (DDR) Gene Mutations in Paired Primary and Metastatic Prostate Cancer Samples. (2021). American Society for Clinical Oncology (ASCO) annual meeting.

DEPARTMENT OF DEFENSE - CONGRESSIONALLY DIRECTED MEDICAL RESEARCH PROGRAMS [Contact Us](#) | [Site Map](#)    

 **CDMRP** Transforming Healthcare through Innovative and Impactful Research

[Home](#) [Research Programs](#) [Funding Opportunities](#) [Consumers](#) [Search Awards & Publications](#) [About Us](#)

[Home](#) / [Research Programs](#) / [Prostate Cancer](#)

News & Highlights

- [Alleviating Immunosuppression to Enhance CAR T-Cell Efficacy in Metastatic Prostate Cancer](#)
- [Blood cell mutations confound prostate cancer liquid biopsy \(external link\)](#)
- [FY20 PCRP Recommended for Funding List](#)
- [Department of Defense Prostate Cancer Research Program Anticipated Funding Opportunities for Fiscal Year 2020 \(FY20\)](#)
- [PCRP Program Summary Sheet](#)

[More...](#)


Prostate Cancer


Vision - Conquer prostate cancer

Prostate cancer is the most commonly diagnosed non-skin cancer in men and is the second most common cause of male death from cancer. In 2020, approximately 191,930 men in the U.S. will be diagnosed with prostate cancer and an estimated 33,330 will die from it¹. Prostate cancer is a real threat to U.S. Service members, as 80% of the active duty population are men. According to the Defense Health Agency (DHA) Medical Surveillance Monthly Report (MSMR), 8,973 new cancers were diagnosed among active duty members of the U.S. Armed Forces between 2005 and 2014, and of these, 1,046 (11.7%) were prostate cancer diagnoses². Prostate cancer incidence, morbidity, and mortality rates also vary markedly by race and ethnicity, with African American (AA) men experiencing the highest rates in the U.S.

Since 1997, the Prostate Cancer Research Program (PCRP) has been dedicated to supporting research focused on eradicating prostate cancer, and specifically seeks to promote:

- Highly innovative, groundbreaking research
- High-impact research with near-term clinical relevance
- The next generation of prostate cancer investigators through mentored research
- Resources that will facilitate translational research

 [Click on Image to View Program Booklet](#)

 [Click on Image to View Strategic Plan](#)

Year 1 and 2:

Dines JN, Shirts BH, Slavin TP, Walsh T, King MC, Fowler DM, and Pritchard CC. Systematic misclassification of missense variants in BRCA1 and BRCA2 "coldspots". Genet Med; 22: 2020; 825-830; published; acknowledgement of federal support (yes).

Nyquist MD, Corella A, Coleman I, De Sarkar N, Kaipainen A, Ha G, Gulati R, Ang L, Chatterjee P, Lucas J, Pritchard C, Risbridger G, Isaacs J, Montgomery B, Morrissey C, Corey E, Nelson PS. Combined TP53 and RB1 Loss Promotes Prostate Cancer Resistance to a Spectrum of Therapeutics and Confers Vulnerability to Replication Stress. Cell Rep; 31: 107669; published; acknowledgement of federal support (yes).

Graham LS, Montgomery B, Cheng HH, Yu EY, Nelson PS, Pritchard C, Erickson S, Alva A, Schweizer MT. Mismatch repair deficiency in metastatic prostate cancer: Response to PD-1 blockade and standard therapies. *PLoS One*; 15; 2020 5:e0233260; published; acknowledgement of federal support (yes).

Chatterjee P, Schweizer MT, Lucas JM, Coleman I, Nyquist MD, Frank SB, Tharakan R, Mostaghel E, Luo J, Pritchard CC, Lam HM, Corey E, Antonarakis ES, Denmeade SR, Nelson PS. Supraphysiological androgens suppress prostate cancer growth through androgen receptor-mediated DNA damage. *Clin Invest*; 10; 2019; 4245-4260. published; acknowledgement of federal support (yes).

Schweizer MT, Gulati R, Beightol M, Konnick EQ, Cheng HH, Klemfuss N, DeSarkar N, Yu EY, Montgomery RB, Nelson PS, and Pritchard CC. Clinical determinants for successful circulating tumor DNA analysis in prostate cancer. *Prostate*; 79: 2019; 701-708; published; acknowledgement of federal support (yes).

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, DeSarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL. Genomic correlates of clinical outcome in advanced prostate cancer. *Proc Natl Acad Sci*; 116: 2019; 11428-11436; published; acknowledgement of federal support (yes).

Schweizer MT, Antonarakis ES, Bismar TA, Guedes LB, Cheng HH, Tretiakova MS, Vakar-Lopez F, Klemfuss N, Konnick EQ, Mostaghel EA, Hsieh AC, Nelson PS, Yu EY, Montgomery RB, True LD, Epstein JI, Lotan TL, and Pritchard CC. Genomic Characterization of Prostatic Ductal Adenocarcinoma Identifies a High Prevalence of DNA Repair Gene Mutations. *JCO Precis Oncol*. 2019; PMID: 31123724; published; acknowledgement of federal support (yes).

Khani F, Wobker SE, Hicks JL, Robinson BD, Barbieri CE, De Marzo AM, Epstein JI, Pritchard CC, Lotan TL. Intraductal carcinoma of the prostate in the absence of high-grade invasive carcinoma represents a molecularly distinct type of in situ carcinoma enriched with oncogenic driver mutations. *J Pathol*; 2019; PMID:30993692; published; acknowledgement of federal support (yes).

Abida W, Cyrta J, Heller G, Prandi D, Armenia J, Coleman I, Cieslik M, Benelli M, Robinson D, Van Allen EM, Sboner A, Fedrizzi T, Mosquera JM, Robinson BD, DeSarkar N, Kunju LP, Tomlins S, Wu YM, Nava Rodrigues D, Loda M, Gopalan A, Reuter VE, Pritchard CC, Mateo J, Bianchini D, Miranda S, Carreira S, Rescigno P, Filipenko J, Vinson J, Montgomery RB, Beltran H, Heath EI, Scher HI, Kantoff PW, Taplin ME, Schultz N, deBono JS, Demichelis F, Nelson PS, Rubin MA, Chinnaiyan AM, Sawyers CL. Genomic correlates of

clinical outcome in advanced prostate cancer. Proc Natl Acad Sci; 116: 2019; 11428-11436; published; acknowledgement of federal support (yes).

Books or other non-periodical, one-time publications. *Report any book, monograph, dissertation, abstract, or the like published as or in a separate publication, rather than a periodical or series. Include any significant publication in the proceedings of a one-time conference or in the report of a one-time study, commission, or the like. Identify for each one-time publication: author(s); title; editor; title of collection, if applicable; bibliographic information; year; type of publication (e.g., book, thesis or dissertation); status of publication (published; accepted, awaiting publication; submitted, under review; other); acknowledgement of federal support (yes/no).*

BOOK CHAPTER (in press): Germline and Somatic Defects in DNA Repair Pathways in Prostate Cancer. Book Title: Prostate Cancer - Cellular and Genetic Mechanisms of Disease Development and Progression. Authors: Sara Arce, Alejandro Athie, Colin C. Pritchard, Joaquin Mateo

Other publications, conference papers and presentations.

Nothing to report

- **Website(s) or other Internet site(s)**

Nothing to report

- **Technologies or techniques**

Nothing to report

- **Inventions, patent applications, and/or licenses**

Nothing to report

- **Other Products**

Nothing to report

7. PARTICIPANTS & OTHER COLLABORATING ORGANIZATIONS

What individuals have worked on the project?

SITE 2 (CNIO)

Name: David Olmos

Project Role: Principal Investigator

Nearest person month worked: 12

Contribution to Project: Dr. Mateo is the PI of this award. Work in Aim 1 samples recovery, review and processing. Aim 2 identification of additional cases for biopsies study in aim 2. Aim3 clinical trial set up.

Funding support: CRIS Cancer Foundation, Spanish Ministry of Science, and this award.

Name: Elena Castro

Project Role: Senior Investigator

Researcher Identifier (e.g. ORCID ID): N/A

Nearest person month worked: 6

Contribution to Project: Optimization of NGS protocols for Shallow WGS (alternative plan for aim 1 low quality/quantity samples) and protocol developments, patients recruitment and trial conduction support in aim 3.

Funding support: Instituto de Salud Carlos III (Spanish NIH), Prostate Cancer Foundation and this award

Name: Alejandro Sanz

Project Role: Postdoctoral Researcher

Researcher Identifier (e.g. ORCID ID): N/A

Nearest person month worked: 6

Contribution to Project: Optimization of NGS protocols and bioinformatic analysis for Shallow WGS (alternative plan for aim 1 low quality/quantity samples) and RNAseq methodologies for Aims 2 and 3.

Funding support: CRIS cancer foundation and this award

Discontinued working on the project and at CNIO by Year 3 Quarter 1

Name: Monica Balsells

Project Role: Senior Trial Manager

Researcher Identifier (e.g. ORCID ID): N/A

Nearest person month worked: 7

Contribution to Project: Clinical trial set up and conduction in aim 3

Funding support: CRIS cancer foundation and this award

Discontinued working on the project and at CNIO by Year 3 Quarter 2

Name: Leticia Rivera

Project Role: Senior trial Manager

Researcher Identifier (e.g. ORCID ID): N/A

Nearest person month worked: 3

Contribution to Project: Work in Aim3 site initiation visits, monitoring visit, CRF reviews, coordinating samples collection shipment and analysis at sites.

Funding support: CRIS cancer foundation

Discontinued working on the project by the end of in Year 3 Quarter 3, and was not replaced by CNIO (his task was assumed by the PI David Olmos)

Name: Ana Maria Gutierrez Pecharroman
Project Role: Pathologist (MD)
Researcher Identifier (e.g. ORCID ID): N/A
Nearest person month worked: 1.5
Contribution to Project: Work in Aim 1 pathology review of samples from PROREPAIR-B.
Funding support: CNIO core funds

Name: Teresa Garcés del Rey
Project Role: Pathology Technician
Researcher Identifier (e.g. ORCID ID): N/A
Nearest person month worked: 2
Contribution to Project: Work in Aim 1 gathering samples, building samples database, and processing samples for DNA extraction
Funding support: other David Olmos grants
Discontinued working on the project and at CNIO by the end of 2020, in Year 3 Quarter 1

Name: Maria Isabel Pacheco _(replaced Teresa Garcés del Rey)
Project Role: Pathology Technician
Researcher Identifier (e.g. ORCID ID): N/A
Nearest person month worked: 3
Funding support: other David Olmos grants
Discontinued working on the project by the end of in Year 4 Quarter 3 (July 2021), and was not replaced by CNIO (his task was assumed by the PI David Olmos and Key investigator Elena Castro)

Has there been a change in the active other support of the PD/PI(s) or senior/key personnel since the last reporting period?

SUPPORT
Olmos, David

Current Funding

Title: Addressing the biological and clinical role of *RBI* loss and DNA Repair defects in lethal prostate cancer

Time Commitments: 3 calendar months

Supporting Agency: Fundación CRIS contra el Cáncer

Contracting/Grants Officer: M^a Dolores Liebanes (proyectos@cniio.es)

Performance Period: 01/Jun/2020 – 30/May/2025

Level of funding:

Project Goals: 1) To study the potential cooperation of *RBI* loss and *BRCA2* loss and other DDR genes in prostate oncogenesis and tumor progression. 2) To identify and validate novel synthetic lethality strategies to treat Rb +/- DDR loss hormone-sensitive prostate cancer using high-throughput screening based on the Crispr/Cas9 system. 3) To study the prognostic role of *RBI* loss combined with *BRCA2* and other DDR defects

Specific Aims:

Overlap: N/A

Title: Identification of lethal subtypes of prostate cancer by integration of transcriptomic, genomic and clinical data

Time Commitments: 3 calendar months

Supporting Agency: Instituto de Salud Carlos III

Contracting/Grants Officer: M^a Dolores Liebanes (proyectos@cniio.es)

Performance Period: 02/Jan/2020 – 30/Dec/2022

Level of funding:

Project Goals: 1) To identify lethal hormonosensitive prostate cancer subgroups integrating genomic, transcriptomic and clinical data; 2) To develop patient derived in vitro and in vivo models of aggressive hormonosensitive prostate cancer

Specific Aims:

Overlap: N/A

Title: Genomic epidemiology and clinical implications of DNA-repair genes and other oncogenic drivers in metastatic hormono-sensitive prostate cancer

Time Commitments: 2 calendar months

Supporting Agency: Instituto Salud Carlos III

Contracting/Grants Officer: M^a Dolores Liebanes (proyectos@cniio.es)

Performance Period: 09/1/2019 – 08/31/2021

Level of funding:

Project Goals: To prospectively assess the prognostic role of DNA repair gene defects and other oncogenic drivers in metastatic hormone-sensitive prostate cancer (mHSPC)

Specific Aims:

Overlap: N/A

What other organizations were involved as partners?

Two other organizations are involved in this Impact Award:

Organization Name: Vall D'Hebron Institute of Oncology (VHIO)

Award # W81XWH-18-1-0758

PC170510P1

PI: Joaquin Mateo

Location of Organization: Barcelona, Spain

Organization Name: University of Washington

Award # W81XWH-18-1-0756

PC170510

PI: Colin Pritchard

Location of Organization: Seattle, WA, United States

8. SPECIAL REPORTING REQUIREMENTS

COLLABORATIVE AWARDS:

QUAD CHARTS:

See attached

9. APPENDICES:

None